GlassScriptPhysician profile
Ioanna Katsa
NPI 1982018644
$11,128.61
in general payments reported to CMS, 2019-2025
28 companies · $4,644 in 2025
The $4,644 reported for 2025 was more than what 82% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $123 · 2021: $2,760 · 2022: $665 · 2023: $1,094 · 2024: $1,843 · 2025: $4,644.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,125 · Travel and Lodging: $1,440.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,124.85 |
| Travel and Lodging | $1,439.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $4,034.55 | 2021-2025 | Onyx Frontier, Symplicity G3, Corevalve Evolut R |
| Abiomed | $1,599.95 | 2021-2025 | Impella |
| Shockwave Medical, INC | $666.58 | 2021-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Boston Scientific Corporation | $612.08 | 2021-2025 | Avvigo Guidance System |
| Stryker Corporation | $548.93 | 2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S, Flowtriever |
| Novartis Pharmaceuticals Corporation | $406.53 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $368.75 | 2021-2025 | |
| Philips North America LLC | $362.89 | 2021-2022 | |
| Cardiovascular Systems INC. | $275.04 | 2021 | |
| Scpharmaceuticals INC. | $263.64 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $244.72 | 2021-2024 | Xarelto |
| Novo Nordisk INC | $213.82 | 2025 | Wegovy, Ozempic |
| Esperion Therapeutics, INC. | $206.61 | 2021-2023 | Nexletol |
| Inari Medical, INC. | $190.24 | 2024-2025 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Penumbra, INC. | $180.23 | 2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $170.90 | 2021-2025 | Dragonfly Opstar |
| Janssen Scientific Affairs, LLC | $124.36 | 2023 | Xarelto |
| Lilly USA, LLC | $121.99 | 2022-2024 | Mounjaro, Zepbound |
| Cardiva Medical, INC. | $121.76 | 2023 | Cardiva Vascade Mvp Vvcs 6-12f |
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.93 | 2023-2025 | Jardiance |
| Lexicon Pharmaceuticals, INC. | $47.12 | 2023 | Inpefa |
| Angiodynamics, INC. | $30.44 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $23.62 | 2023 | Opsumit |
| E.R. Squibb & Sons, L.L.C. | $19.97 | 2025 | Eliquis |
| Amgen INC. | $19.73 | 2023 | Repatha |
| Merck Sharp & Dohme LLC | $19.06 | 2023 | Verquvo, Belsomra |
| Chiesi USA, INC. | $16.83 | 2025 | Kengreal |
| Spectrawave, INC | $12.35 | 2025 | Starlight Imaging Catheter, Hypervue Imaging System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ioanna Katsa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.